Yvonne Greenstreet, Alnylam CEO

Up­dat­ed: Al­ny­lam scores OK for sec­ond-gen hAT­TR ther­a­py as the space heats up

The lat­est ri­val to Al­ny­lam’s drug for hered­i­tary transthyretin-me­di­at­ed (hAT­TR) amy­loi­do­sis is here — and it comes from Al­ny­lam it­self.

Four years af­ter the ground­break­ing ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.